BJMO - volume 9, issue 6, november 2015
T. Vermassen PhD, S. Rottey MD, PhD
From the 25th till the 29th of September, Vienna was host for the 18th ECCO – 40th ESMO European Cancer Congress. Immunotherapy was a very important theme for this year’s venue which hosted 18.500 registered attendees. This report will highlight 4 key studies concerning renal cell carcinoma and metastatic prostate cancer presented during the presidential sessions of the meeting.
(BELG J MED ONCOL 2015;9:244–49)
Read moreBJMO - volume 9, issue 4, august 2015
T. Vermassen PhD, S. Rottey MD, PhD
From May 29th till June 2nd, Chicago was host for the 2015 ASCO annual meeting. The theme for this year’s congress was ‘Illumination and Innovation: Transforming Data into Learning’. With over 30,000 registered attendees from over 120 countries worldwide and more than 6,000 submitted abstracts, this year’s meeting was a great success. This report will highlight 12 key studies concerning genitourinary cancers presented during the meeting.
(BELG J MED ONCOL 2015;9:158–63)
Read moreBJMO - volume 9, issue 3, july 2015
T. Vermassen PhD, P. de Visschere MD, G Villeirs MD, PhD, D. Schrijvers MD, PhD, S. Rottey MD, PhD
Due to the success of last year, a second national Belgian multidisciplinary scientific meeting on urological cancers was held with the cooperation of medical oncologists (BSMO), urologists (BAU) and radiation oncologists (ABRO/BVRO). It was a great opportunity to build bridges between these three important specialisations involved in the treatment of urological cancers.
The steering committee of the meeting consisted of J. P. Machiels, G. Pelgrims, S. Rottey (members of BSMO); L. Hoekx, S. Joniau, T. Roumeguere (members of BAU); O. De Hertogh, G. De Meerleer and Y. Neybuch (members of ABRO/BVRO). The second meeting, held in Brussels on March 28th, 2015 was a great success with more than 100 attendees of the different specialisations involved.
In this meeting report you will find summaries of the lectures of Dr De Visschere (Radiologist) and Dr Schrijvers (Medical Oncologist).
(BELG J MED ONCOL 2015;9(3):113–16)
Read moreBJMO - volume 9, issue 1, february 2015
Z. El Ali MD, PhD, D. Van Brummelen MD, P. Wolter MD, S. Rottey MD, PhD, S. Altintas MD, PhD, D. Schallier MD, PhD, P. Debruyne MD, PhD, C. Gennigens MD, F. Van Aelst MD, S. Sideris MD, T. Gil MD, N. Sirtaine MD, L. D’Hondt MD, PhD, D. Luyten MD, C. Focan MD, PhD, G. Matus MD, M. Rasschaert MD, G. Pelgrims MD, the BSMO Renal Cancer Task Force Group
Almost 30% of patients with renal cell cancer present initially with advanced stage IV disease. In the past decade, the management of the metastatic renal cell cancer has been revolutionised by the knowledge of its molecular biology and development of targets against vascular endothelial growth factor and mammalian target of rapamycin pathways. In this paper we present recommendations based on a thorough review of available guidelines and data from the phase III randomised controlled trials that evaluated new agents in patients with advanced metastatic renal cancer.
(BELG J MED ONCOL 2015;9(1):16–24)
BJMO - volume 8, issue 5, november 2014
T. Vermassen PhD, S. Rottey MD, PhD
From the 26th till the 30th of September, Madrid was host for the 39th annual congress of the European Society of Medical Oncology (ESMO). The theme of this years’ meeting, that was hosted at the IFEMA – Feria de Madrid, was ‘Precision Medicine in Cancer Care. This report will highlight 10 key studies concerning genitourinary cancers presented during the meeting.
(BELG J MED ONCOL 2014;8(4):143–6)
Read moreBJMO - volume 8, issue 5, december 2014
T. Vermassen PhD, J. M. Kerst MD, PhD, B. Tombal MD, PhD, S. Rottey MD, PhD
The Belgian multidisciplinary meeting on urological cancers was initiated as the first national multidisciplinary scientific meeting of medical oncologists (BSMO), urologists (BAU) and radiotherapists (ABRO-BVRO). It was a great opportunity to build bridges between these three important specialisations involved in the treatment of uro-oncology.
The steering committee of the meeting consisted of J. P. Machiels, G. Pelgrims, S. Rottey (BSMO); L. Hoekx, S. Joniau, T. Roumeguere (BAU); O. De Hertogh, G. De Meerleer and Y. Neybuch (ABRO-BVRO). The first meeting, held in Brussels on March 29th, 2014 was a great success with more than 150 attendees of the different specialisations involved.
(BELG J MED ONCOL 2014;8(5):224–7)
Read moreBJMO - volume 7, issue 4, september 2013
C. Van Praet MD, D. De Maeseneer MD, N. Lumen MD, PhD, S. Rottey MD, PhD
Since the 1940’s the androgen receptor has been the main target for systemic therapy in prostate cancer. Classic hormonal therapy aims at lowering serum testosterone levels or block the androgen receptor ligand-binding domain. Despite disease progression, castration-resistant prostate cancer remains predominantly androgen-driven as novel secondary hormonal therapy with abiraterone acetate or enzalutamide has demonstrated increased overall survival. Promising androgen synthesis inhibitors (orteronel, galeterone), androgen receptor inhibitors (ARN-509, EPI-001, AZD3514) and heat-shock protein modulators are under investigation. Given the upcoming arsenal of systemic therapies and the molecular heterogeneity of castration-resistant prostate cancer, patient-tailored therapy strategies are being explored.
(BELG J MED ONCOL 2013;7(3):111–8)
Read more
Top
